scholarly journals Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.

Gut ◽  
1994 ◽  
Vol 35 (5) ◽  
pp. 590-598 ◽  
Author(s):  
J Dent ◽  
N D Yeomans ◽  
M Mackinnon ◽  
W Reed ◽  
F M Narielvala ◽  
...  
Keyword(s):  
Reflux Oesophagitis ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial ◽  
Prevention Of Relapse ◽  
Reflux Œsophagitis

scholarly journals Does Dimethicone Increase the Efficacy of Antacids in the Treatment of Reflux Oesophagitis?

1986 ◽  
Vol 79 (10) ◽  
pp. 584-587 ◽  
Author(s):  
A L Ogilvie ◽  
Michael Atkinson
Keyword(s):  
Reflux Oesophagitis ◽  
Oesophageal Reflux ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Antacid Therapy ◽  
Gel Preparation ◽  
Small Advantage ◽  
Reflux Œsophagitis

Dimethicone is a common additive to antacids, although its value in the treatment of reflux oesophagitis is unproven. Its efficacy was assessed by comparing the effect of a dimethicone-containing antacid gel (Asilone Gel) with a simple antacid gel in a double-blind trial in 45 patients with reflux oesophagitis. Thirty-eight patients completed the eight-week course of therapy. Antacid therapy alone resulted in a significant improvement of both symptoms and oesophagitis in gastro-oesophageal reflux. The inclusion of dimethicone in the antacid gel preparation did not confer any benefit in terms of symptomatic assessment but did confer a small advantage with regard to objective markers of oesophageal inflammation, suggesting that a dimethicone-containing antacid is of value in the treatment of symptomatic gastro-oesophageal reflux.

S601 EFFICACY AND SAFETY OF A SUBCUTANEOUS DICLOFENAC FORMULATION IN THE MANAGEMENT OF ACUTE PAIN: A RANDOMISED, DOUBLE-BLIND TRIAL

2011 ◽  
Vol 5 (S1) ◽  
pp. 269-270
Author(s):  
T. Dietrich ◽  
R. Leeson ◽  
B. Zielińska-Kaźmierska ◽  
M. Opadczuk ◽  
E. Kozieł ◽  
...  
Keyword(s):  
Acute Pain ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients

1997 ◽  
Vol 171 (1) ◽  
pp. 73-77 ◽  
Author(s):  
I. Pelc ◽  
P. Verbanck ◽  
O. Le Bon ◽  
M. Gavrilovic ◽  
K. Lion ◽  
...  
Keyword(s):  
Animal Models ◽  
Alcohol Drinking ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial ◽  
Efficacy Parameters ◽  
Clinical Conditions ◽  
Alcohol Dependent

BackgroundAcamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions.MethodIn order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day).ResultsFor all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe.ConclusionThis study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.

Sign in / Sign up

Export Citation Format

Share Document